MRI Reveals Missed Cancerous Breast Lesions

CHICAGO — Magnetic resonance imaging done prior to treatment for breast cancer can reveal cancer missed by mammography and ultrasonography, yielding more accurate information about the extent of disease, according to a poster presented at the annual meeting of the Radiological Society of North America.

“We found almost 29% more cancer by doing the magnetic resonance imaging before surgery or radiation therapy than we thought we had diagnosed with standard mammography, ultrasound, and clinical examination,” said Dr. Gillian Newstead of the University of Chicago in an interview. Identifying more cancer up front will influence the course of treatment and ideally produce a more positive long-term outcome, she said.

The researchers classified newly diagnosed breast cancers in 140 women (mean age 56.5 years), of which 53.5% were invasive ductal carcinoma (IDC) with extensive intraductal component (EIC). Additional lesions identified by MRI in 40 women included 26 in the same quadrant, 11 in a different quadrant, and 3 in the contralateral breast. Specifically, 23 of the lesions were identified as IDC with EIC, 6 as IDC, 6 as ductal carcinoma in situ, and 5 as invasive lobular cancer. Clinical management was changed in 31 of the 40 women: 20 underwent more extensive surgery, 8 were converted from breast conservation to mastectomy, and 3 were given additional neoadjuvant chemotherapy.

Although mammography and ultrasonography are still the primary imaging methods for breast cancer screening and diagnosis, the higher soft tissue contrast and gadolinium-enhanced images obtained by MRI improve the sensitivity of detection and allow more accurate evaluation of the cancer. Most breast cancers enhance rapidly after IV injection of contrast agents because of higher vascularity and the angiogenic factors that produce an increase in capillary permeability.

“The MR is looking at the new blood vessel growth, or angiogenesis, in tumors and it's a functional test in that sense, so we see lesions that may not show up on mammograms, especially in dense breasts. And there are some tumors that grow in such a way that makes them more difficult to perceive on a mammogram,” she added.

“Patients underwent imaging in the prone position with the breasts gently immobilized within lateral compression plates. Contrast injection was made with IV administration of 0.1 mmol/kg gadodiamide followed by a 20-mL saline flush at the rate of 2.0 mL per second. MR images were acquired using a 1.5-T scanner with use of a dedicated breast coil,” the investigators said. The resolution on the MRI machine was 1.6 mm.

Hospitals have been slow to assimilate MRI into clinical practice because there have been a lot of different techniques proposed by academic centers, Dr. Newstead said. “That's becoming less of an issue as our magnets are getting faster and we don't have to make as many compromises; so I would say that any person with a fairly modern magnet and a modern breast coil should be able to achieve satisfactory resolution both spatially and temporally,” she said.

MRI has found a home at the University of Chicago's breast imaging section, not only for pretreatment assessment but also to detect cancer recurrence post treatment and to screen high-risk women. “Early detection of local recurrence improves long-term survival, but postoperative mammographic and ultrasound evaluation often is limited, especially in patients with dense, fibroglandular tissue and postsurgical or postradiation fibrosis,” the authors wrote, noting that recurrent tumor exhibits early enhancement.

“MR is a sensitive modality for detection of early recurrent tumor, and breast cancer recurrence must be differentiated from acute and subacute posttreatment changes. Most recurrent tumor, unlike unrecognized residual tumor, usually presents at least 2 years following breast conservation treatment. Normal parenchymal enhancement usually is diminished after breast irradiation. Recurrent tumor may therefore be readily visible in the postradiation breast,” they said.

False-positive findings are not a problem with high-resolution MRI and correct procedure, Dr. Newstead said. “When we find something on MR that wasn't seen before on mammography or ultrasound, typically we'll bring the patient back for a repeat ultrasound and mammogram. If we see something, we'll do a biopsy right then. But if we can't find anything [with conventional imaging]—which happens in about 40% of our cases—and MR is the only finding, then we'll bring the patient back and repeat the MRI study. If it still looks worrisome, we'll go ahead and biopsy at the same time, so she only has to come back once,” Dr. Newstead explained.

'We found almost 29% more cancer by doing the magnetic resonance imaging.' DR. NEWSTEAD

CHICAGO — Magnetic resonance imaging done prior to treatment for breast cancer can reveal cancer missed by mammography and ultrasonography, yielding more accurate information about the extent of disease, according to a poster presented at the annual meeting of the Radiological Society of North America.

“We found almost 29% more cancer by doing the magnetic resonance imaging before surgery or radiation therapy than we thought we had diagnosed with standard mammography, ultrasound, and clinical examination,” said Dr. Gillian Newstead of the University of Chicago in an interview. Identifying more cancer up front will influence the course of treatment and ideally produce a more positive long-term outcome, she said.

The researchers classified newly diagnosed breast cancers in 140 women (mean age 56.5 years), of which 53.5% were invasive ductal carcinoma (IDC) with extensive intraductal component (EIC). Additional lesions identified by MRI in 40 women included 26 in the same quadrant, 11 in a different quadrant, and 3 in the contralateral breast. Specifically, 23 of the lesions were identified as IDC with EIC, 6 as IDC, 6 as ductal carcinoma in situ, and 5 as invasive lobular cancer. Clinical management was changed in 31 of the 40 women: 20 underwent more extensive surgery, 8 were converted from breast conservation to mastectomy, and 3 were given additional neoadjuvant chemotherapy.

Although mammography and ultrasonography are still the primary imaging methods for breast cancer screening and diagnosis, the higher soft tissue contrast and gadolinium-enhanced images obtained by MRI improve the sensitivity of detection and allow more accurate evaluation of the cancer. Most breast cancers enhance rapidly after IV injection of contrast agents because of higher vascularity and the angiogenic factors that produce an increase in capillary permeability.

“The MR is looking at the new blood vessel growth, or angiogenesis, in tumors and it's a functional test in that sense, so we see lesions that may not show up on mammograms, especially in dense breasts. And there are some tumors that grow in such a way that makes them more difficult to perceive on a mammogram,” she added.

“Patients underwent imaging in the prone position with the breasts gently immobilized within lateral compression plates. Contrast injection was made with IV administration of 0.1 mmol/kg gadodiamide followed by a 20-mL saline flush at the rate of 2.0 mL per second. MR images were acquired using a 1.5-T scanner with use of a dedicated breast coil,” the investigators said. The resolution on the MRI machine was 1.6 mm.

Hospitals have been slow to assimilate MRI into clinical practice because there have been a lot of different techniques proposed by academic centers, Dr. Newstead said. “That's becoming less of an issue as our magnets are getting faster and we don't have to make as many compromises; so I would say that any person with a fairly modern magnet and a modern breast coil should be able to achieve satisfactory resolution both spatially and temporally,” she said.

MRI has found a home at the University of Chicago's breast imaging section, not only for pretreatment assessment but also to detect cancer recurrence post treatment and to screen high-risk women. “Early detection of local recurrence improves long-term survival, but postoperative mammographic and ultrasound evaluation often is limited, especially in patients with dense, fibroglandular tissue and postsurgical or postradiation fibrosis,” the authors wrote, noting that recurrent tumor exhibits early enhancement.

“MR is a sensitive modality for detection of early recurrent tumor, and breast cancer recurrence must be differentiated from acute and subacute posttreatment changes. Most recurrent tumor, unlike unrecognized residual tumor, usually presents at least 2 years following breast conservation treatment. Normal parenchymal enhancement usually is diminished after breast irradiation. Recurrent tumor may therefore be readily visible in the postradiation breast,” they said.

False-positive findings are not a problem with high-resolution MRI and correct procedure, Dr. Newstead said. “When we find something on MR that wasn't seen before on mammography or ultrasound, typically we'll bring the patient back for a repeat ultrasound and mammogram. If we see something, we'll do a biopsy right then. But if we can't find anything [with conventional imaging]—which happens in about 40% of our cases—and MR is the only finding, then we'll bring the patient back and repeat the MRI study. If it still looks worrisome, we'll go ahead and biopsy at the same time, so she only has to come back once,” Dr. Newstead explained.

'We found almost 29% more cancer by doing the magnetic resonance imaging.' DR. NEWSTEAD

CHICAGO — Magnetic resonance imaging done prior to treatment for breast cancer can reveal cancer missed by mammography and ultrasonography, yielding more accurate information about the extent of disease, according to a poster presented at the annual meeting of the Radiological Society of North America.

“We found almost 29% more cancer by doing the magnetic resonance imaging before surgery or radiation therapy than we thought we had diagnosed with standard mammography, ultrasound, and clinical examination,” said Dr. Gillian Newstead of the University of Chicago in an interview. Identifying more cancer up front will influence the course of treatment and ideally produce a more positive long-term outcome, she said.

The researchers classified newly diagnosed breast cancers in 140 women (mean age 56.5 years), of which 53.5% were invasive ductal carcinoma (IDC) with extensive intraductal component (EIC). Additional lesions identified by MRI in 40 women included 26 in the same quadrant, 11 in a different quadrant, and 3 in the contralateral breast. Specifically, 23 of the lesions were identified as IDC with EIC, 6 as IDC, 6 as ductal carcinoma in situ, and 5 as invasive lobular cancer. Clinical management was changed in 31 of the 40 women: 20 underwent more extensive surgery, 8 were converted from breast conservation to mastectomy, and 3 were given additional neoadjuvant chemotherapy.

Although mammography and ultrasonography are still the primary imaging methods for breast cancer screening and diagnosis, the higher soft tissue contrast and gadolinium-enhanced images obtained by MRI improve the sensitivity of detection and allow more accurate evaluation of the cancer. Most breast cancers enhance rapidly after IV injection of contrast agents because of higher vascularity and the angiogenic factors that produce an increase in capillary permeability.

“The MR is looking at the new blood vessel growth, or angiogenesis, in tumors and it's a functional test in that sense, so we see lesions that may not show up on mammograms, especially in dense breasts. And there are some tumors that grow in such a way that makes them more difficult to perceive on a mammogram,” she added.

“Patients underwent imaging in the prone position with the breasts gently immobilized within lateral compression plates. Contrast injection was made with IV administration of 0.1 mmol/kg gadodiamide followed by a 20-mL saline flush at the rate of 2.0 mL per second. MR images were acquired using a 1.5-T scanner with use of a dedicated breast coil,” the investigators said. The resolution on the MRI machine was 1.6 mm.

Hospitals have been slow to assimilate MRI into clinical practice because there have been a lot of different techniques proposed by academic centers, Dr. Newstead said. “That's becoming less of an issue as our magnets are getting faster and we don't have to make as many compromises; so I would say that any person with a fairly modern magnet and a modern breast coil should be able to achieve satisfactory resolution both spatially and temporally,” she said.

MRI has found a home at the University of Chicago's breast imaging section, not only for pretreatment assessment but also to detect cancer recurrence post treatment and to screen high-risk women. “Early detection of local recurrence improves long-term survival, but postoperative mammographic and ultrasound evaluation often is limited, especially in patients with dense, fibroglandular tissue and postsurgical or postradiation fibrosis,” the authors wrote, noting that recurrent tumor exhibits early enhancement.

“MR is a sensitive modality for detection of early recurrent tumor, and breast cancer recurrence must be differentiated from acute and subacute posttreatment changes. Most recurrent tumor, unlike unrecognized residual tumor, usually presents at least 2 years following breast conservation treatment. Normal parenchymal enhancement usually is diminished after breast irradiation. Recurrent tumor may therefore be readily visible in the postradiation breast,” they said.

False-positive findings are not a problem with high-resolution MRI and correct procedure, Dr. Newstead said. “When we find something on MR that wasn't seen before on mammography or ultrasound, typically we'll bring the patient back for a repeat ultrasound and mammogram. If we see something, we'll do a biopsy right then. But if we can't find anything [with conventional imaging]—which happens in about 40% of our cases—and MR is the only finding, then we'll bring the patient back and repeat the MRI study. If it still looks worrisome, we'll go ahead and biopsy at the same time, so she only has to come back once,” Dr. Newstead explained.

'We found almost 29% more cancer by doing the magnetic resonance imaging.' DR. NEWSTEAD